PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21975872-0	2012	Imatinib ameliorates renal morphological changes in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension.	Imatinib Mesylate	0-8	angiotensinogen	Rattus norvegicus	95-101	
16432052-10	2006	In vitro, imatinib blocked angiotensin II-induced activation of the PDGFRbeta and significantly decreased fibroblast proliferation and collagen production.	Imatinib Mesylate	10-18	angiotensinogen	Rattus norvegicus	27-41	
26510503-7	2016	c-Abl small interfering RNA (siRNA) and STI571 (c-Abl inhibitor) provided protection against Ang II-induced podocyte injury, suppressed the Ang II-induced c-Abl-SHIP2 interaction and SHIP2 phosphorylation, and maintained a stable level of nephrin phosphorylation.	Imatinib Mesylate	40-46	angiotensinogen	Rattus norvegicus	140-146	
15197170-8	2004	The findings of attenuation of vascular hypertrophy and matrix deposition by imatinib indicate that transactivation of the PDGFR in vivo contributes to the growth factor-like effects of Ang II, independent of its hemodynamic effects or its ability to induce TGF-beta gene expression.	Imatinib Mesylate	77-85	angiotensinogen	Rattus norvegicus	186-192	
33598481-12	2020	Both sunitinib and imatinib pre-treatment increased Angiotensin II-induced intracellular Ca2+ mobilization, with only sunitinib resulting in a significant effect and also causing increased CaMKII activation via oxidation.	Imatinib Mesylate	19-27	angiotensinogen	Rattus norvegicus	52-66	
26510503-7	2016	c-Abl small interfering RNA (siRNA) and STI571 (c-Abl inhibitor) provided protection against Ang II-induced podocyte injury, suppressed the Ang II-induced c-Abl-SHIP2 interaction and SHIP2 phosphorylation, and maintained a stable level of nephrin phosphorylation.	Imatinib Mesylate	40-46	angiotensinogen	Rattus norvegicus	93-99